<p>Celcuity, Inc.（纳斯达克代码：CELC - 获取免费报告）的股票在目前覆盖该公司的五家研究公司中获得了 “买入” 的共识评级，MarketBeat.com 报道。五位研究分析师对该股票给予了买入推荐。在过去一年中更新了对该股票覆盖的经纪人中，平均一年价格目标为 56.50 美元。</p>
<p>CELC 最近成为几份分析师报告的主题。Needham &amp; Company LLC 将 Celcuity 的股票目标价从 74.00 美元下调至 70.00 美元，并在 8 月 15 日的报告中对该股票设定了 “买入” 评级。Stifel Nicolaus 于 7 月 1 日的研究报告中开始覆盖 Celcuity 的股票。他们对该股票设定了 “买入” 评级和 30.00 美元的价格目标。Leerink Partners 在 7 月 28 日的研究报告中将 Celcuity 的股票目标价从 28.00 美元上调至 60.00 美元，并给予该股票 “跑赢大盘” 的评级。HC Wainwright 在 8 月 18 日的研究报告中将 Celcuity 的股票目标价从 50.00 美元上调至 66.00 美元，并给予该股票 “买入” 评级。最后，Guggenheim 在周一的研究报告中开始覆盖 Celcuity，并对该股票设定了 “买入” 评级。</p>
<p><strong>阅读我们关于 CELC 的最新报告</strong></p>
<h2>Celcuity 股票表现</h2>
<p>Celcuity 股票在周一开盘价为 51.88 美元。Celcuity 的十二个月最低价为 7.57 美元，最高价为 63.06 美元。该股票的市值为 22 亿美元，市盈率为-15.04，贝塔值为 0.72。公司的流动比率为 4.58，速动比率为 4.58，债务与股本比率为 2.24。该公司的 50 日移动平均价格为 42.86 美元，200 日移动平均价格为 22.13 美元。</p>
<p>Celcuity（纳斯达克代码：CELC - 获取免费报告）最近于 8 月 14 日宣布了其季度财报。公司报告每股收益为（1.04 美元），低于分析师的共识预期（0.90 美元）14 美分。整体来看，研究分析师预计 Celcuity 在本年度的每股收益为-2.62 美元。</p>
<h2>内部人士下注</h2>
<p>在其他 Celcuity 的新闻中，董事 David Dalvey 于 7 月 28 日出售了 100,000 股公司的股票。该股票以平均价格 43.98 美元出售，总价值为 4,398,000.00 美元。出售后，该董事在公司持有 125,000 股，价值约为 5,497,500 美元。这笔交易代表了他们持有股票的 44.44% 的减少。该出售在向证券交易委员会提交的文件中披露，您可以通过此链接访问。15.78% 的股票由公司内部人士持有。</p>
<h2>Celcuity 的机构交易</h2>
<p>大型投资者最近增加或减少了对该公司的持股。Rhumbline Advisers 在第二季度将其在 Celcuity 的持股增加了 1.2%。Rhumbline Advisers 目前持有 42,697 股公司股票，价值 570,000 美元，此前在该期间购买了 503 股。Intech Investment Management LLC 在第二季度将其在 Celcuity 的持股增加了 5.2%。Intech Investment Management LLC 目前持有 14,855 股公司股票，价值 198,000 美元，此前在该期间购买了 734 股。BNP Paribas Financial Markets 在第二季度将其在 Celcuity 的持股增加了 78.9%。BNP Paribas Financial Markets 目前持有 2,647 股公司股票，价值 35,000 美元，此前在该期间购买了 1,167 股。GAMMA Investing LLC 在第一季度将其在 Celcuity 的持股增加了 1,237.4%。GAMMA Investing LLC 目前持有 1,324 股公司股票，价值 131,000 美元，此前在该期间购买了 1,225 股。最后，Tema Etfs LLC 在第二季度将其在 Celcuity 的持股增加了 8.9%。Tema Etfs LLC 目前持有 17,011 股公司股票，价值 227,000 美元，此前在该期间购买了 1,392 股。目前 63.33% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Celcuity</h2>
<p>（获取免费报告）</p>
<p>Celcuity Inc 是一家临床阶段的生物技术公司，专注于开发针对美国各种实体肿瘤的靶向疗法。公司的 CELsignia 诊断平台利用患者的活肿瘤细胞来识别驱动患者癌症的特定异常细胞过程及相关的靶向疗法。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Celcuity</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>3 只被忽视的价值股，预计在利率下降时大幅上涨</li>
<li>最佳股票低于 5.00 美元</li>
<li>Hims &amp; Hers 股票因医疗保健降息狂潮而飙升</li>
<li>纳斯达克股票交易所是什么？</li>
<li>在美联储降息后，PNC 可能会迎来抵押贷款再融资热潮</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Celcuity 吗？</h2>
<p>在考虑 Celcuity 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Celcuity 并不在名单上。</p>
<p>虽然 Celcuity 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CELC

<p>Celcuity, Inc.（纳斯达克代码：CELC）获得了五家研究公司的共识 “买入” 评级。平均一年目标价为 56.50 美元。最近的分析师报告显示，Needham & Company 将其目标价从 74.00 美元下调至 70.00 美元，而 Leerink Partners 则将其目标价从 28.00 美元上调至 60.00 美元。Celcuity 的股票开盘价为 51.88 美元，12 个月的价格区间为 7.57 美元至 63.06 美元。该公司报告每股季度亏损为（1.04 美元），未能达到预期。机构投资者持有 63.33% 的股份，内部人士持有 15.78%</p>

<p>Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) have been given a consensus rating of &#34;Buy&#34; by the five research firms that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $56.50.</p>
<div class="lb-trans"><p>Celcuity, Inc.（纳斯达克代码：CELC - 获取免费报告）的股票在目前覆盖该公司的五家研究公司中获得了 “买入” 的共识评级，MarketBeat.com 报道。五位研究分析师对该股票给予了买入推荐。在过去一年中更新了对该股票覆盖的经纪人中，平均一年价格目标为 56.50 美元。</p>
</div><p>CELC has been the topic of several recent analyst reports. Needham &amp; Company LLC cut their price target on shares of Celcuity from $74.00 to $70.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, August 15th. Stifel Nicolaus started coverage on shares of Celcuity in a research note on Tuesday, July 1st. They set a &#34;buy&#34; rating and a $30.00 price objective on the stock. Leerink Partners increased their price objective on shares of Celcuity from $28.00 to $60.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, July 28th. HC Wainwright increased their price objective on shares of Celcuity from $50.00 to $66.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, August 18th. Finally, Guggenheim initiated coverage on Celcuity in a research report on Monday. They set a &#34;buy&#34; rating on the stock.</p>
<div class="lb-trans"><p>CELC 最近成为几份分析师报告的主题。Needham &amp; Company LLC 将 Celcuity 的股票目标价从 74.00 美元下调至 70.00 美元，并在 8 月 15 日的报告中对该股票设定了 “买入” 评级。Stifel Nicolaus 于 7 月 1 日的研究报告中开始覆盖 Celcuity 的股票。他们对该股票设定了 “买入” 评级和 30.00 美元的价格目标。Leerink Partners 在 7 月 28 日的研究报告中将 Celcuity 的股票目标价从 28.00 美元上调至 60.00 美元，并给予该股票 “跑赢大盘” 的评级。HC Wainwright 在 8 月 18 日的研究报告中将 Celcuity 的股票目标价从 50.00 美元上调至 66.00 美元，并给予该股票 “买入” 评级。最后，Guggenheim 在周一的研究报告中开始覆盖 Celcuity，并对该股票设定了 “买入” 评级。</p>
</div><p><strong>Read Our Latest Report on CELC</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CELC 的最新报告</strong></p>
</div><h2>Celcuity Price Performance</h2>
<div class="lb-trans"><h2>Celcuity 股票表现</h2>
</div><p>Shares of Celcuity stock opened at $51.88 on Monday. Celcuity has a twelve month low of $7.57 and a twelve month high of $63.06. The stock has a market capitalization of $2.20 billion, a P/E ratio of -15.04 and a beta of 0.72. The company has a current ratio of 4.58, a quick ratio of 4.58 and a debt-to-equity ratio of 2.24. The business's fifty day moving average price is $42.86 and its 200 day moving average price is $22.13.</p>
<div class="lb-trans"><p>Celcuity 股票在周一开盘价为 51.88 美元。Celcuity 的十二个月最低价为 7.57 美元，最高价为 63.06 美元。该股票的市值为 22 亿美元，市盈率为-15.04，贝塔值为 0.72。公司的流动比率为 4.58，速动比率为 4.58，债务与股本比率为 2.24。该公司的 50 日移动平均价格为 42.86 美元，200 日移动平均价格为 22.13 美元。</p>
</div><p>Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.14). As a group, research analysts anticipate that Celcuity will post -2.62 earnings per share for the current year.</p>
<div class="lb-trans"><p>Celcuity（纳斯达克代码：CELC - 获取免费报告）最近于 8 月 14 日宣布了其季度财报。公司报告每股收益为（1.04 美元），低于分析师的共识预期（0.90 美元）14 美分。整体来看，研究分析师预计 Celcuity 在本年度的每股收益为-2.62 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Celcuity news, Director David Dalvey sold 100,000 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the sale, the director owned 125,000 shares in the company, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. 15.78% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Celcuity 的新闻中，董事 David Dalvey 于 7 月 28 日出售了 100,000 股公司的股票。该股票以平均价格 43.98 美元出售，总价值为 4,398,000.00 美元。出售后，该董事在公司持有 125,000 股，价值约为 5,497,500 美元。这笔交易代表了他们持有股票的 44.44% 的减少。该出售在向证券交易委员会提交的文件中披露，您可以通过此链接访问。15.78% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of Celcuity</h2>
<div class="lb-trans"><h2>Celcuity 的机构交易</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its holdings in shares of Celcuity by 1.2% during the second quarter. Rhumbline Advisers now owns 42,697 shares of the company's stock valued at $570,000 after purchasing an additional 503 shares during the period. Intech Investment Management LLC increased its holdings in shares of Celcuity by 5.2% during the second quarter. Intech Investment Management LLC now owns 14,855 shares of the company's stock valued at $198,000 after purchasing an additional 734 shares during the period. BNP Paribas Financial Markets increased its stake in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after buying an additional 1,167 shares during the period. GAMMA Investing LLC increased its stake in Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock valued at $131,000 after buying an additional 1,225 shares during the period. Finally, Tema Etfs LLC increased its stake in Celcuity by 8.9% during the 2nd quarter. Tema Etfs LLC now owns 17,011 shares of the company's stock valued at $227,000 after buying an additional 1,392 shares during the period. 63.33% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该公司的持股。Rhumbline Advisers 在第二季度将其在 Celcuity 的持股增加了 1.2%。Rhumbline Advisers 目前持有 42,697 股公司股票，价值 570,000 美元，此前在该期间购买了 503 股。Intech Investment Management LLC 在第二季度将其在 Celcuity 的持股增加了 5.2%。Intech Investment Management LLC 目前持有 14,855 股公司股票，价值 198,000 美元，此前在该期间购买了 734 股。BNP Paribas Financial Markets 在第二季度将其在 Celcuity 的持股增加了 78.9%。BNP Paribas Financial Markets 目前持有 2,647 股公司股票，价值 35,000 美元，此前在该期间购买了 1,167 股。GAMMA Investing LLC 在第一季度将其在 Celcuity 的持股增加了 1,237.4%。GAMMA Investing LLC 目前持有 1,324 股公司股票，价值 131,000 美元，此前在该期间购买了 1,225 股。最后，Tema Etfs LLC 在第二季度将其在 Celcuity 的持股增加了 8.9%。Tema Etfs LLC 目前持有 17,011 股公司股票，价值 227,000 美元，此前在该期间购买了 1,392 股。目前 63.33% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Celcuity</h2>
<div class="lb-trans"><h2>关于 Celcuity</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.</p>
<div class="lb-trans"><p>Celcuity Inc 是一家临床阶段的生物技术公司，专注于开发针对美国各种实体肿瘤的靶向疗法。公司的 CELsignia 诊断平台利用患者的活肿瘤细胞来识别驱动患者癌症的特定异常细胞过程及相关的靶向疗法。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Celcuity</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>3 Overlooked Value Stocks Set to Surge as Rates Drop</li>
<li>Best Stocks Under $5.00</li>
<li>Hims &amp; Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>After the Fed's Rate Cut, PNC Could See a Mortgage Refinance Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Celcuity</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>3 只被忽视的价值股，预计在利率下降时大幅上涨</li>
<li>最佳股票低于 5.00 美元</li>
<li>Hims &amp; Hers 股票因医疗保健降息狂潮而飙升</li>
<li>纳斯达克股票交易所是什么？</li>
<li>在美联储降息后，PNC 可能会迎来抵押贷款再融资热潮</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CELC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Celcuity Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Celcuity 吗？</h2>
</div><p>Before you consider Celcuity, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Celcuity 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Celcuity 并不在名单上。</p>
</div><p>While Celcuity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Celcuity 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Celcuity, Inc.（NASDAQ:CELC）被分析师给予 “买入” 平均评级